Isis' Balancing Act: Diversify With Cancer, But Avoid High-Stakes Gambles
Isis tried a delicate balancing act during its May 20 pipeline update: it sought to accentuate its progress in branching out into cancer drug development, while also reassuring investors that its oncology spend is relatively modest and doesn't introduce major risk
You may also be interested in...
Lilly holds option to reacquire LY2275796 at the start of Phase III.
Genzyme/Isis expect to file NDA for the cholesterol-lowering antisense drug in mid-2010.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011